StageZero Life Sciences Ltd
TORONTO, ON / ACCESSWIRE / July 29, 2021 / StageZero Life Sciences, Ltd. (TSX:SZLS) ("StageZero" or the "Company"), a healthcare company working to reduce the risk of cancer and other chronic diseases through early detection and intervention, today provided an update on its planned acquisition of Health Clinics Limited. The two companies have made excellent progress on the development of the definitive agreement for the transaction and are close to conclusion. However due to the complexity the companies have agreed to extend the timeframe and exclusivity for its completion to August 14, 2021.
"We continue to make progress on what is a complex, international transaction that will ultimately enable more patients to benefit from our combined strengths," said Chairman and CEO James Howard-Tripp. "Our planned acquisition of Health Clinics Limited promises to be transformative for StageZero and will greatly expand our existing partnership, including the broader use of telehealth capabilities to reach millions of consumers and employers who want to keep themselves and their employees healthy and avert chronic disease."
About StageZero Life Sciences, Ltd.
StageZero Life Sciences is dedicated to the early detection of multiple diseases through whole blood tests. The Company's next-generation test, Aristotle®, is the first-ever multi-cancer panel for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer. StageZero's full service, telehealth platform includes access to physicians and phlebotomists who can prescribe and draw samples for individuals and groups, and the Company operates a CAP accredited and CLIA certified high-complexity reference laboratory in Richmond, Virginia. In addition, leveraging its specialty in polymerase chain reaction (PCR) testing for the early identification of cancer through blood, StageZero also provides both COVID PCR testing (swab and saliva) and blood test analysis (Antibody testing). For more information, please visit www.stagezerolifesciences.com.
Forward-Looking Statements
This press release contains forward-looking statements identified by words such as "expects", "will" and similar expressions, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties that could cause the Company's actual events to differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements, except as required by law.
For further information please contact:
Rebecca Greco
Investor Relations
Tel: 1-855-420-7140 ext. 1838
rgreco@stagezerols.com
SOURCE: StageZero Life Sciences Ltd
View source version on accesswire.com:
https://www.accesswire.com/657723/StageZero-Life-Sciences-Provides-Update-on-Planned-Acquisition-of-Health-Clinics-Limited
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Formerra to Supply Foster Medical Compounds Across the Americas15.7.2025 16:45:00 CEST | Press release
Following GEON's acquisition of Foster, LLC, this new agreement expands Formerra's healthcare polymer portfolio with life-saving medical compounds. ROMEOVILLE, IL / ACCESS Newswire / July 15, 2025 / Formerra, a leader in performance materials distribution, today announced an agreement with GEON® Performance Solutions that designates Formerra as the preferred distributor of Foster®, LLC medical compounds in North America and South America. The agreement follows GEON's acquisition of Foster, LLC, and builds on Formerra's long-standing, global partnership with GEON for flexible and rigid PVC and filled polypropylene materials. "This expanded partnership equips our customers with a broader set of proven medical-grade solutions while leveraging Formerra's technical guidance and robust supply-chain capabilities," said Kelly Wessner, Vice President, Key Accounts, Formerra. "Foster's brand strength and GEON's investment momentum create powerful growth potential for these materials and our cust
FairWinds Migrates from .COM to .FAIRWINDS, Showcasing Leadership in Strategic Internet Addressing15.7.2025 16:00:00 CEST | Press release
WASHINGTON, DC / ACCESS Newswire / July 15, 2025 / FairWinds Partners, the world's leading domain name strategy consultancy, has completed the migration of its website from fairwindspartners.com to home.fairwinds. "This transition is more than a domain change. It reflects our belief in the future of .BRAND top-level domains," said FairWinds founder Josh Bourne. "Our move to .FAIRWINDS reinforces the strategic value that these top-level domains offer and our evolution from a pioneering domain name advisory firm to the trusted partner for global brands navigating the digital landscape via the address bar." Unlike second-level domains like google.com, top-level domains reside on the internet's root servers -- the foundation of the internet's naming system. .BRAND top-level domains are not publicly available and are used exclusively by the brand owner. ".BRAND top-level domains provide a powerful way to amplify, control, and secure a brand's digital presence while giving visitors visual pr
QorusDocs Reports 360% Increase in Customers Using AI to Manage Proposals, Acquires Shark Finesse to Build Unified AI-Powered Value and Proposal Platform15.7.2025 13:00:00 CEST | Press release
BELLEVUE, WA / ACCESS Newswire / July 15, 2025 / QorusDocs, an AI-powered proposal management software company that streamlines creation of pitches, proposals and request for proposal (RFP) responses, today announced that its customers' use of AI to manage proposals has grown 360% year over year, and that it has acquired Shark Finesse Ltd, a United Kingdom-based AI-powered customer value management software. "AI is completely transforming how business development teams win business, and QorusDocs is at the forefront," said Ray Meiring, CEO of QorusDocs. "The majority of our customers now rely on AI to manage proposals. We're at a pivotal moment, and with the acquisition of Shark Finesse, we're poised to deliver on companies' full revenue enablement journey, from proving value to winning the deal." QorusDocs Acquires Shark Finesse With Shark Finesse joining QorusDocs, the company's vision is to enable business development and proposal teams to prove value early in the revenue cycle, wit
AATec Medical and Northway Biotech Announce Partnership to Develop Industrial Production Process for ATL-105 Targeting Lung Disease15.7.2025 09:50:00 CEST | Press release
Partnership established to develop and scale production of ATL-105, a novel recombinant version of alpha-1 antitrypsin Lead indication is non-CF bronchiectasis; ATL-105 targets disease drivers through a broad multimodal mechanism of action VILNIUS, LT / ACCESS Newswire / July 15, 2025 / AATec Medical GmbH ("AATec"), a biotech company developing a multi-product platform for the treatment of respiratory diseases, and Northway Biotech ("Northway Biotech" or "NBT"), a global Contract Development and Manufacturing Organization (CDMO), today announced a partnership for manufacturing process development and analytical development of AATec's lead product candidate, ATL-105, a proprietary, inhaled therapy based on recombinant alpha-1 antitrypsin (AAT) for non-cystic fibrosis bronchiectasis (NCFB).AATec Medical and Northway Biotech Announce Partnership Under the agreement, Northway Biotech will leverage its expertise in biologics manufacturing to develop and scale the production process for ATL-
IXOPAY Surges Past 500 Certified Adapters, Solidifies Leadership in Enterprise-Grade Payment Orchestration15.7.2025 06:00:00 CEST | Press release
With 200 PSPs and 300 payment methods, IXOPAY is unlocking faster global expansion, improved approval rates, and full-stack control for enterprise merchants. LEHI, UT / ACCESS Newswire / July 15, 2025 / As global commerce accelerates, enterprise merchants are hitting a wall - their legacy payment stacks weren't built for the scale, complexity, or speed modern commerce demands. To stay competitive, merchants need infrastructure that adapts across markets, providers, and payment methods without costly rewrites or vendor lock-in. IXOPAY, a global leader in enterprise-grade payment orchestration, is addressing that challenge head-on with the announcement it has reached 500 certified adapters, connecting 200 payment service providers (PSPs) and 300 payment methods through a single, vendor-agnostic API. Payment orchestration is rapidly emerging as vital infrastructure for modern payments, and its effectiveness depends on the scale and breadth of the adapter ecosystem. IXOPAY's industry-leadi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom